Post by PressReleaseon Mar 08, 2023 7:45am
102 Views
Post# 35325306
New Press Release - Revive Therapeutics Provides Update From Type C Meeting with FDA for Amended Protocol Agreement of Phase 3 Clinical Study for Bucillamine in the Treatment of COVID-19